Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

  • Hematologic Oncology Treatment Center

    Dana-Farber/Brigham and Women's Cancer Care

    As a patient in the Center for Hematologic Oncology, you will be treated by a dedicated team committed to delivering safe, high-quality patient care. Our specialists will work with you to create a treatment plan tailored to your type of cancer and your lifestyle, to achieve the best possible outcome.

    About the Center

    HemOnc patient and a clinician

    The Center for Hematologic Oncology provides specialized care for all types of cancers of the blood, including leukemia, lymphoma, multiple myeloma and Waldenström's macroglobulinemia, as well as related disorders of the blood, such as aplastic anemia and myelodysplasia.

    The center also includes the bone marrow/stem cell transplantation program, which is one of the largest and most experienced in the world.

    We develop personalized, comprehensive treatment plans for all our patients, offering the latest therapies and supportive resources, and taking your particular needs into account.

    Our specialized centers and programs

    Adult Leukemia Program

    The Adult Leukemia Program provides care for patients with leukemia and related bone marrow disorders, including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and related bone marrow disorders, such as myelodysplasia and myelofibrosis.

    Lymphoma Program

    The Lymphoma Program provides care for the many varieties of lymphoid malignancies, including Non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, B-cell neoplasms, and T-cell neoplasms.

    Chronic Lymphocytic Leukemia Program

    The Chronic Lymphocytic Leukemia Program provides care for patients with with chronic lymphocytic leukemia (CLL), and offers access to clinical trials of promising new therapies.

    Multiple Myeloma Program

    The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics provide care to patients with multiple myeloma, including promising new therapies through clinical trials.

    Waldenström's Macroglobulinemia Program

    The Bing Center for Waldenström's Macroglobulinemia provides care and new therapies through clinical trials to patients with Waldenström's macroglobulinemia and related Immunoglobulin M (IgM) disorders.

    Bone Marrow/Stem Cell Transplantation Program

    The center's Bone Marrow/Stem Cell Transplantation Program was one of the first in the world and is now one of the largest and busiest in the United States. Since its inception in 1972, our hematopoietic stem cell transplant specialists have performed more than 8,200 transplants for the treatment of blood cancers and related blood disorders.

    Adult Histiocyte Disorders Center

    The Adult Histiocyte Disorders Center provides highly effective, personalized treatment options for patients with adult histiocytosis and histiocyte disorders – rare diseases resulting from over-production of white blood cells (histiocytes), which can lead to tumors and organ damage.

    Older Adult Hematologic Malignancy (OHM) Program

    The OHM Program is a research and clinical service that addresses the specialized needs of blood cancer patients who are age 75 and older.

    Other hematologic malignancies we treat include:

    • Agnogenic myeloid metaplasia
    • Aids-related malignancies
    • Amyloidosis
    • Aplastic anemia and paroxysmal nocturnal hemoglobinuria (PNH)
    • Autoimmune disorders
    • Burkitt lymphoma
    • Castleman's syndrome
    • Chronic myeloid monocytic leukemia (CMML)
    • CNS primary lymphoma
    • Congenital disorders of blood production (sickle cell anemia, thalassemia), Blackfan-Diamond, Shwachman-Diamond, and Dyskeratosis Congenita syndromes
    • Eosinphilia
    • Essential thrombocytosis
    • Hairy cell leukemia
    • Histocytosis
    • Jak 2 disease
    • Langerhans cell histiocytosis
    • Leukocytosis
    • Leukopenia
    • Lymphoproliferative disorder
    • Mastocytosis
    • Megablastic anemia
    • Monoclonal paraprotein/M-GUS
    • Mycosis fungoides/cutt-cell lymphoma
    • Myelodysplastic syndromes
    • Myelofibrosis
    • Monoclonal gammmopathies
    • Myeloid metaplasia
    • Myeloproliferative disorders (polycythemia, myelofibrosis, thrombocythemia)
    • Neutropenia pancytopenia
    • NK cell lymphoma
    • Philadelphia positive disease
    • Polycythemia vera
    • Testicular cancer
    • Testicular choriocarcinoma
    • Thrombocytopenia
    • Thrombocytosis
    • Waldenström's macroglobulinemia

    Read our Insight blog for information and inspiration about treatment for blood cancers at

    Our Treatment Approach

    To make sure your care is as seamless as possible, a dedicated team of clinicians, who are highly specialized experts in your type of blood cancer, will care for you throughout the treatment process, from diagnosis though long-term follow-up.

    As a patient in the Center for Hematologic Oncology, you will be treated by a dedicated care team that includes oncologists, surgeons, hematologists, physician assistants, nurses and clinical social workers who are committed to delivering high-quality, safe, patient care.

    We develop personalized, comprehensive treatment plans for all our patients, offering the latest therapies and supportive resources, and taking your particular needs into account.

    We provide comprehensive services for treatment, including imaging, pathology, and radiation oncology. We also communicate with your referring physician throughout your treatment, including collaboration for follow-up care closer to your home where available.

    In addition to conventional treatment approaches, you may have the opportunity to participate in clinical trials that offer access to new, innovative treatments for your type of cancer.

    Our clinicians are actively involved in clinical research, working closely with laboratory investigators to examine a variety of treatment strategies, including:

    • Chemotherapies and combinations of existing treatments;
    • Radiation therapies;
    • Novel targeted therapies, which block specific molecules involved in the growth and progression of cancer cells;
    • Immune therapies, such as vaccine and cellular therapy; and
    • Bone marrow/stem cell transplantation, including traditional and reduced-intensity transplant, using related, unrelated or umbilical cord blood cells for transplant.

    We recognize that you and your family face many decisions and life changes. To assist you and help you make informed choices, we offer support services and education programs, resource centers and libraries, financial counseling, and low-cost, short-and long-term housing.

    A variety of services and programs also support your care, including:

    One distinguishing area of expertise is in our treatment of older adults (over 60 years old). Older adults with cancers of the blood often have different needs from younger adults, for example, a higher risk for heart disease, diabetes, or kidney problems, which may limit treatment options.

    To address the specific needs of older patients, we offer:

    • clinical trials specifically for adults 60 years old and over
    • stem cell transplant options for older patients with proven experience with transplanting patients well into their 70s
    • cutting-edge approaches to care, coupled with access to specialized supportive services

    Treatment Team

    Our providers work together across a range of specialty areas to coordinate fully integrated, personalized care from your initial diagnosis through long-term follow up.

    Your treatment team includes physicians, physician assistants (PAs) nurse practitioners, clinical and research nurses. Laboratory investigators, clinical care coordinators, clinical social workers, and nutritionists will also be part of your care team.

    For a list of our specialized care teams, please visit our program sections below:


    Clinical Research

    More than 100 clinical trials are currently underway in the Center for Hematologic Oncology. The combined resources of our partner organizations within Dana-Farber/Harvard Cancer Center make us the largest cancer research center in the nation.

    Leukemia, myelodysplasia and myeloproliferative disorders research

    The leukemia team works to develop more effective, less toxic treatments for acute leukemia and related disorders, including myelodysplastic syndrome, chronic myeloid leukemia and myeloproliferative disorders.

    Our clinical research focuses on understanding how leukemia cells develop and creating new ways to block their growth. We are also taking the innovative step of treating adult acute lymphoblastic leukemia (ALL) patients using treatments that have proved successful in pediatric patients.

    Related story:

    Lymphoma research

    Our lymphoma research focuses on translating laboratory findings into less toxic treatments. We are committed to investigating and understanding the genetic pathways that enable lymphoma cells to survive and manipulating them with targeted therapies to improve outcomes.

    Our research program features a variety of trials specifically for chronic lymphocytic leukemia (CLL) patients, focusing on familial CLL, genomic studies and testing of novel therapies.

    Multiple myeloma research

    The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics encompasses a large team of laboratory-based and clinical scientists investigating more effective therapies for multiple myelomas. Promising new therapies are rooted in a "bench-to-bedside" approach, where laboratory discoveries are rapidly translated into the clinical setting as part of treatment.

    Waldenström's macroglobulinemia research

    The main goal of clinical research at the Bing Center for Waldenström's macroglobulinemia is to take laboratory discoveries to the clinic, where they can benefit patients.

    Trials include studies aimed at improving outcomes of patients undergoing biological therapies that attempt to destroy the tumor cells directly; evaluating supportive therapies; and examining the genetic basis of the disease.

    Contact Us

    New Patients

    If you have never been seen before at Dana-Farber/Brigham and Women's Cancer Center, please call 877-442-3324, or use this online form to make an appointment. For all other inquiries, please call 617-632-5138.

    You may schedule your first appointment for as soon as the next day. After scheduling, one of our nurses will call you to answer your questions and help you prepare for the appointment.

    Pediatric patients should call Dana-Farber/Boston Children's Cancer and Blood Disorders Center at 888-PEDI ONC (733-4662)

    Current Patients

    Contact your doctor directly, or for general inquiries, call the Hematologic Malignancies program at 617-632-6140.

    For Physicians and Physician Office Staff

    Monday through Friday from 8:30 a.m.-5:00 p.m., physician offices can call 855-281-2811 to access the Hematologic Malignancies department directly. During these hours, a Hematologic Malignancies administrative team member will take your call, address your inquiry, or route it accordingly. You may also contact us via email at



    Vice President of Hematopoietic Stem Cell Transplantation and Cell Therapies
    Amy Emmert

    Administrative Directors, Disease Center Operations
    Katie Kupferberg

    Amy Kazmouski

    For more information about the stem cell/bone marrow donor search process, please call our Donor Services team at 866-875-DFCI (3324) or 617-632-2561.

    Lymphoma second opinions at satellite centers

    Dana-Farber/New Hampshire Oncology-Hematology

  •   Email
  •   Print
  •   Share
  • Highest ranked in New England

  • How Our Blood Cancer Patients Rate Dana-Farber

  • Dana-Farber Highlights from ASH 2016

    • Paul Richardson, MD Learn about the advances in blood cancer care and research presented by Dana-Farber physicians and scientists at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, December 3-6, 2016.
  • Rapid Heme Panel: A Major Advance in Blood Cancer Testing

  • Online Resource for Precision Cancer Medicine

    • Clinicians at Dana-Farber/
      Brigham and Women's Cancer Center are now armed with specialized tests to create a precise "tumor profile" for each patient's cancer. Learn about the latest thinking in precision cancer medicine for certain types of blood cancers and explore a searchable database of clinical trials that focus on targeted therapies by disease, gene, and mutation.
  • Jay Bradner, MD, Delivers SIDTALK at Dana-Farber

    • Jay Bradner, MD In the spirit of the illuminating TED Talks, our Joint Visiting Committee recently heard a dynamic SIDTALKScience, Innovation, and Discovery — from leading researcher James (Jay) Bradner, MD, reporting from the frontier of his field. View Dr. Bradner's SIDTALK. 
  • New consortium brings blood cancer trials to communities

    • Irene Ghobrial, MD Robert Soiffer, MD Dana-Farber Cancer Institute and the Leukemia & Lymphoma Society have created the Blood Cancer Research Partnership (BCRP) — an innovative new consortium bringing cutting-edge clinical trials to community medical centers across the U.S. The BCRP is directed by Irene Ghobrial, MD, and Robert Soiffer, MD.
  • Hematologic Malignancies: Physician resources

  • Patients Share Their Stories

    • patient Arieana CarcieriPatients with blood cancers and related disorders share their journeys from diagnosis of their disease through treatment.